What's Happening?
The IMA Group has announced the acquisition of the Chicago Research Center (CRC), a clinical research site specializing in central nervous system (CNS) and sleep disorders. This acquisition marks IMA's sixth dedicated CNS research site and ninth clinical research acquisition in the past four years. CRC, known for its expertise in Phase I-IV trials, operates a research sleep lab and has conducted over 125 studies on CNS, mood, and sleep disorders. The acquisition allows IMA to expand its reach and accelerate study timelines, ultimately improving access to innovative treatments for patients in Chicago and beyond.
Why It's Important?
The acquisition of CRC by IMA Group is significant as it enhances IMA's capabilities in CNS and sleep research, areas of growing need in the U.S. With approximately 35% of U.S. adults reporting insufficient sleep, expanding research capacity in this field addresses a pressing public health priority. The acquisition also strengthens IMA's national platform, allowing it to expand trial capacity and diversity, and contribute to areas of urgent need like sleep apnea and mental health. This move positions IMA to better serve government agencies, payers, employers, and life sciences sponsors across the country.
What's Next?
IMA plans to extend its sleep research capabilities across additional sites, addressing the unmet needs in sleep disorders. The company will continue to conduct Phase II-IV trials in various therapeutic areas, including obesity, diabetes, cardiovascular disease, infectious disease, and vaccines. By operating a flexible national network that supports site-based, hybrid, and fully decentralized models, IMA aims to connect with diverse patients at more than 150 sites nationwide. This strategic expansion is expected to enhance IMA's sponsor relationships and contribute to the development of therapies for CNS and sleep disorders.
